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Abstract 
Domestic cats suffer from a range of inherited genetic diseases, many of which display similarities 
with equivalent human conditions. Developing cellular models for these inherited diseases would 
enable drug discovery, benefiting feline health and welfare as well as enhancing the potential of 
cats as relevant animal models for translation to human medicine. Advances in our understanding 
of these diseases at the cellular level have come from the use of induced pluripotent stem cells 
(iPSCs). iPSCs are capable of differentiating into derivatives of all three germ layers, therefore 
overcoming the limitations of primary differentiated cells and the ethical concerns of using 
embryonic stem cells. No studies however report the generation of iPSCs from domestic cats 
(fiPSCs). Feline adipose derived fibroblasts were infected with amphotropic retrovirus containing 
the coding sequences for human Oct4, Sox2, Klf4, cMyc and Nanog. Isolated iPSC clones were 
expanded on mouse inactivated embryonic fibroblasts in the presence of feline leukaemia 
inhibitory factor (LIF). Retroviral delivery of human pluripotent genes gave rise to putative fiPSC 
colonies within 5-7 days. These iPS-like cells required foetal bovine serum and feline LIF for 
maintenance. Colonies were domed with refractile edges, similar to mouse iPSCs.  
Immunocytochemistry demonstrated positive staining for stem cell markers: alkaline 
phosphatase, Oct4, Sox2, Nanog and SSEA1. Cells were negative for SSEA4. Expression of 
endogenous feline Nanog was confirmed by qPCR. The cells were able to differentiate in vitro 
into cells representative of the three germ layers. These results confirm the generation of the first 
induced pluripotent cells from domestic cats. These cells will provide valuable models to study 
genetic diseases and explore novel therapeutic strategies.  
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Introduction 
Inducing pluripotency is a process where differentiated cells are reprogrammed into a 
pluripotent or embryonic-stem cell like state [1]. These induced pluripotent stem cells 
(iPSCs) are then able to differentiate into derivatives of all three germ layers, generating 
great promise for their use in regenerative medicine and disease modelling, whilst 
avoiding the ethical implications of using embryonic stem cells [2,3]. They can also be 
derived from patients with disease causing genetic mutations, allowing patient-specific 
iPSC lines to be developed for in vitro drug testing. For example, iPSC lines harbouring 
mutations known to cause hypertrophic cardiomyopathy (HCM) effectively recapitulate 
the disease at the single cell level, allowing discovery of novel drug targets for clinical 
therapy [4]. iPSC derived cardiomyocytes have further been shown to highlight potential 
drug side-effects in specific patients and predict drug response [5]. Additionally, the 
consistency and ability to control for other factors makes iPSC disease models a rapid 
drug discovery system [6]. Recent discoveries in gene editing mean that iPSC lines can 
be mutated, providing a powerful tool for analysing disease-causing mutations whilst 
controlling for genetic background [7].  
 
iPSCs were first generated from mouse cells and subsequently from human cells [3,8,9]. 
Since then research focussed on optimising human iPSC generation and culture has 
allowed the whole process to be xeno-free and footprint-free (without inserted genetic 
sequences), providing a platform for clinical research [10]. Studies deriving iPSCs from 
other species have shown the process is applicable across a wide range of animals. For 
example, multiple groups have derived iPSCs from dogs, horses, sheep, pigs, goats and 
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other wild species [11–18]. With respect to felids, there are two studies describing the 
generation of iPSCs from wild species [19,20].  Currently no studies have described the 
generation of iPSCs from domestic cats, an important veterinary species. Cats also 
provide a spontaneous large animal model for important human diseases, including 
diabetes, cardiac disease as well as a wide range of genetic conditions, allowing a one 
health approach to disease [21–24]. For example, HCM in cats closely resembles human 
HCM at the genetic, clinical and pathological level [25]. Interestingly a causative mutation 
identified in cats is also present in a human family [26]. HCM has a high prevalence in the 
feline population, affecting around 15% of all cats and increasing to almost 30% in those 
over 9 years of age [27]. Given the importance and similarities of disease in both humans 
and cats, discovering novel drug targets would be beneficial to the health of both species. 
Drug discovery utilising feline iPSCs could be translated to the feline clinic, where benefits 
can be assessed more rapidly due to the high prevalence, rapid disease progression and 
reduced regulation compared to human clinical trials.  
 
IPSCs derived from species other than mouse or human remain cultured under conditions 
that are not fully optimised or defined. Many still rely on original methods of retroviral 
insertion of human genes, use of undefined animal-derived media and maintenance on 
inactivated mouse embryonic fibroblasts [15,28]. Much of what is known about pluripotent 
stem cells from diverse species is based on knowledge of embryonic stem cell culture. In 
cats, there are no studies deriving bona fide embryonic stem cells. There are two reports 
of embryonic stem-like cells, however these could not be maintained under the culture 
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conditions indefinitely, raising the possibility that either the cells were not true ESCs, or 
that the culture conditions were not able to sustain a pluripotent state [29,30]. 
 
The development of a method to derive iPSCs from feline somatic cells would advance 
feline genetic and embryological research, which is currently hampered also by the lack 
of ESCs. These methods would provide researchers with a platform to further optimise 
iPSC culture from a novel species and realise the same potential as for human iPSCs. 
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Material and Methods 
 
Fibroblast cell culture 
Feline adipose tissue derived fibroblasts, isolated as described elsewhere [31], had been 
cryopreserved in the liquid phase of nitrogen at passage 0 (P0) to P1 prior to 
commencement of this project as approved by the Ethics and Welfare Committee 
(Approval number: URN 2012 1192) at the Royal Veterinary College (RVC). Cells were 
thawed rapidly in a 37°C water bath, then re-suspended in media consisting of Dulbecco’s 
Modified Eagles Medium (DMEM; Thermo Fisher), 10% v/v foetal bovine serum (FBS; 
Thermo Fisher), 1% v/v L-glutamine (Thermo Fisher) and 10 ng mL-1 basic fibroblast 
growth factor (bFGF, Peprotech). All cultures were maintained at 37°C, 5% CO2 in 
humidified air.  
 
Feeder cell preparation 
Proliferating mouse embryonic fibroblasts (MEFs) were purchased at P3 (EmbryoMax, 
Sigma-Aldrich). The cells were cultured in the same media as for feline fibroblasts but 
without bFGF. MEFs were thawed onto 0.2% gelatin (Sigma Aldrich) coated 75 cm2 flasks 
at a density of 1.3 x 104 cells cm-2 and passaged 1:3 at 70-80% confluence. At passage 
five, MEFs were mitotically inactivated with 10 µg ml-1 mitomycin C (Stem Cell 
Technologies) for 2 h and cryopreserved in Cell Banker 2 (AMS Bio) at a concentration 
of 1 x 106 cells ml-1. 
 
Retroviral production and transfection 
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Moloney murine leukaemia virus (MMLV) based retroviral plasmids (pMXs) containing the 
coding sequences for human Oct4 (Addgene 17217), Sox2 (Addgene 17218), Klf4 
(Addgene 17219), c-Myc (Addgene 17220) and Nanog (Addgene 18115) were purchased 
from Addgene. A GFP containing plasmid (Cell Biolabs) was used to assess for 
transfection efficiency. For production of MMLV virus, Platinum-A packaging cells 
(Cambridge Bioscience), which express the gag, pol and env genes, were plated 24 h 
prior to transfection at a density of 1 x 105 cells cm-2 in 60 mm cell culture dishes, one 
dish per retroviral vector plasmid. Next, 6 µg of each of the vectors was transfected to 
Platinum-A cells separately using Lipofectamine 2000 (Thermo Fisher) according to the 
manufacturers’ instruction. To optimise transfection efficiency, feline fibroblasts were 
transfected with GFP vector at a range of seeding densities (500 - 1 x 104 cells cm-2), 
cultured for 24, 48 or 72 h and in media with and without bFGF 24 h. Following this 
optimisation, fibroblasts were plated 24 h before transfection at a density of 500 cells cm-
2 in 100 mm cell culture dishes, in media containing bFGF. Supernatants containing virus 
particles were collected from the packaging cells after 48 h, filtered through a 0.45 µm 
filter, supplemented with polybrene (8 µg mL-1, Sigma Aldrich) and 10 ng mL-1 bFGF. The 
five transcription factor virus supernatants were pooled in equal volumes and added to 
the fibroblasts. We did not quantify viral titre prior to infection since storage of MMLV 
leads to reduced viral titre making this impractical. Instead we used a parallel GFP 
experiment to monitor that viral production and cell infection was successful. The 
procedure was repeated after removal of the previous viral supernatant 24 h later for a 
total of two rounds of transfection. 
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Generation and culture of iPSCs 
At 24 h following the second retroviral infection, inactivated MEFs (iMEFs) were added to 
the plate of feline fibroblasts at a density of 2 x 104 cm-2 in fibroblast media. The following 
day the media was changed to feline iPSC media, which consisted of DMEM-GlutaMax, 
20% v/v ESC-qualified FBS (Thermo Fisher), 1% v/v non-essential amino acids (Thermo 
Fisher), 0.1 mM 2-mercaptoethanol (Thermo Fisher) and 10 ng mL-1 feline leukaemia 
inhibitory factor (fLIF, Kingfisher Biotech). Colonies were manually picked based on ESC-
like morphology at 7-10 days using a dissecting microscope and P-20 pipette tip. Colonies 
were placed into a 96-well plate containing 20 µL of 0.25% trypsin-EDTA (Thermo Fisher), 
incubated at room temperature for 5 min and then mixed by pipetting to obtain single 
cells. This cell suspension was then transferred to one well of a 24-well plate, which had 
been seeded with iMEFs 24 h previously. Individual colonies were treated separately to 
obtain clonal cell lines. Hereafter feline iPSCs were passaged as single cells using 0.25% 
trypsin-EDTA at a 1:6 to 1:10 ratio every 2-3 days. Cells for cryopreservation were re-
suspended in CellBanker 2 media, transferred to -80°C in a Mr Frosty freezing container 
(Nalgene), then transferred to liquid nitrogen storage after 24 h.  
 
Embryoid body formation and differentiation 
To form embryoid bodies feline iPSCs were treated with 0.25% trypsin-EDTA for 5 mins 
and cells were transferred to CELLSTAR cell repellent surface 24-well plates (Greiner 
Bio-one) using a 1:1 split ratio from a confluent 6 well plate. Media was changed to iPSC 
media without fLIF. After 4-5 days embryoid bodies were collected and re-distributed onto 
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0.2% gelatin coated 48-well plates and allowed to differentiate for 3 weeks before 
antibody staining. 
 
Alkaline phosphatase staining and immunocytochemistry 
Alkaline phosphatase activity of feline iPSC at passages 2, 15 and 22 was determined 
using VECTOR Red Alkaline Phosphatase (Red AP) Substrate Kit (Vector Laboratories). 
Cells for immunocytochemistry at passages 15-22 were plated in 48-well plates for all 
staining procedures and allowed to adhere for at least 24 h. Immunostaining procedures 
were performed at room temperature following removal of culture media. Cells were 
washed once with Dulbecco’s phosphate buffered saline (DPBS) and fixed in 4% 
paraformaldehyde (Sigma-Aldrich) for 15 min. Fixative was then removed and the cells 
were permeabilised using 0.4% Triton X-100 (Sigma-Aldrich) for 15 min. Cells were 
washed with 0.05% Tween 20/DPBS (Sigma Aldrich) and blocked with 10% goat serum 
(Abcam) for 1 h. Cells were washed again and incubated with the primary antibody for 
1.5 h. Following three washes cells were incubated with the secondary antibody for 1 h. 
Cells were then washed again three times and nuclei counterstained using NucBlue 
ReadyProbe according to the manufacturers’ instructions (Thermo Fisher). The primary 
and secondary antibodies used for ICC are listed in Table 1.  Images were captured using 
an EVOS FL colour imaging system (Thermo Fisher).  
 
Flow cytometry  
To determine the GFP positive percentage, cells were detached from culture vessels 
using 0.25% trypsin-EDTA 48 h post second transfection. Cells were pelleted (400 g for 
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5 min) and re-suspended in FACSFlow (BD Bioscience). Samples were acquired in 
polystyrene FACS tubes on a BD FACS Calibur flow cytometer (BD Bioscience). The 
instrument was calibrated using CaliBRITE 3 colour FACS Comp beads (BD Bioscience) 
before acquiring and analysing each set of samples using CellQuest Pro software (BD 
Bioscience). Non-infected cells were acquired in order to set the forward and side scatter 
parameters to centre the cell population on the scatter plot. Fluorescence intensity was 
adjusted to set the non-infected cells within 100 – 101 on the log scale axis. Cells were 
then acquired with an event count set to a total of 1 x 104 events. Data was analysed 
using FlowJo software (FlowJo, Version 10, LLC). 
 
Reverse transcription and quantitative real-time polymerase chain reaction 
RNA was extracted from non-infected fibroblasts, infected fibroblasts and iPSCs at 
passages 1-22 using the GenElute™ Mammalian Total RNA Miniprep Kit (Sigma-Aldrich). 
Genomic DNA contamination was removed using the TURBO DNA-free kit (Thermo 
Fisher). Then 1 µg of RNA was reverse transcribed using the SensiFAST cDNA synthesis 
kit (Bioline). Quantitative real-time PCR (qPCR) was performed using 2 µL of cDNA 
template, non-reverse transcribed control or water using the SensiMix SYBR green No-
ROX kit (Bioline) and run on a CFX96 Real Time PCR Detection System (Bio-rad) with 
the following conditions: 95°C for 10 min, then 44 cycles of 95°C for 15 s, 60°C for 15s, 
72°C for 15s. A final ramp of 60-90°C at 0.5°C increments was used for melt curve 
analysis. Five housekeeping genes were first analysed to ascertain stability across 
different cell types (non-infected fibroblasts, pooled infected fibroblasts and three iPSC 
lines). RPS7 was scored as the most stable using RefFinder, which compares analyses 
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from 4 computational programs (Delta CT, BestKeeper, Normfiner and Genorm; 
Supplementary Figure 1). This was then used to normalise qPCR data for other genes 
analysed. The primer sequences are given in Table 2.  
 
Karyotyping 
Feline iPSCs were incubated for 18 h at 37°C in standard cell culture conditions in media 
containing 0.13 µg mL-1 colcemid (KaryoMax; Thermo Fisher). Next cells were 
dissociated using 0.25% trypsin-EDTA, pelleted (300g for 3 min) and resuspended by 
adding 4 mL of 0.075 M KCL drop-wise to the cell pellet and then incubated at 37°C for 
25 min. Then 10 drops of fixative (3:1 methanol/acetic acid) were added and cells mixed 
by inversion and incubated for 10 min at room temperature. Cells were then pelleted as 
before, re-suspended in 4 mL fixative and incubated for 30 min at room temperature. 
Following a final centrifugation cells were resuspended in 2 mL of fixative and 
chromosomes visualised using DAPI staining. At least 20 metaphase spreads were 
counted, with a haploid number of 38 considered normal.  
 
Statistical analysis 
The SPSS software package (IBM, version 23 for Mac) was used for statistical analysis. 
Data was assessed for normality using histogram analysis. All data are presented as the 
mean ± SEM of three individual clonal iPSC lines derived from the same reprogramming 
experiment, with samples run at least in triplicate. Fibroblast data is obtained from 3 
independent analyses of the same cell line or transfected pool that generated the iPSC 
lines. Comparisons between two independent samples were performed using Student’s 
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two-tailed T-test and between three or more groups using one-way ANOVA with post-hoc 
Tukey analysis. A p value of < 0.05 was considered significant.  
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Results 
Amphotropic retrovirus infects feline cells with high efficiency 
Transduction efficiency of feline fibroblasts was assessed by transfection with a GFP 
containing amphotropic MMLV. After a number of optimisations, the transfection 
efficiency could be increased from an initial 10-20% to >99% (Figure 1a and b). Seeding 
the cells at low density (500 cells cm-2) in media containing bFGF 24 h prior to transfection 
led to the highest GFP expression.  
 
Infected feline fibroblasts express human pluripotent genes 
Once we confirmed efficient transduction, feline fibroblasts were transduced with pooled 
viral supernatant containing coding sequences for five human pluripotency associated 
genes (OSKMN). Immunocytochemistry demonstrated expression of the pluripotent 
factors at the protein level with a nuclear localisation as expected (Figure 2a).  RT-qPCR 
confirmed that the feline cells had high gene expression levels of integrated human 
pluripotent factors (Figure 2b). 
  
Feline iPSCs require feline leukaemia inhibitory factor for maintenance 
Following a number of different derivation conditions we ascertained a protocol for feline 
iPSC induction. A timeline for this is shown in Figure 3a. Feline fibroblasts were seeded 
24 h prior to transduction at low density in media containing bFGF. Following 2 rounds of 
retroviral infection 24 h apart, iMEFs are added directly to the plate of infected feline 
fibroblasts. Colonies are then observed from day 3 to day 7 (Figure 3b-e). The feline iPSC 
(fiPSC) colonies were observed to be initially relatively two dimensional, peripherally well 
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demarcated and with cells exhibiting a high nuclear to cytoplasm ratio, more typical of 
human embryonic stem cell morphology (Figure 3c). Following the first passage colonies 
formed a domed morphology with a phase bright surface and retractile edges more typical 
of mouse ESC morphology (Figure 3d and e). iPSCs were able to be propagated using a 
1:6 - 1:10 split ratio every 2-3 days for over 20 passages.  
 
fiPSC were further observed to be dependent on FBS and feline leukaemia inhibitory 
factor (fLIF) for maintenance. Culture of fiPSC in media containing knock-out serum 
replacer (KSR) or removing fLIF led to loss of colony morphology within 3-5 days (data 
not shown). Media containing bFGF with or without LIF allowed small colonies to form but 
they did not progress beyond 10-20 cells and could not be expanded (data not shown). 
Additionally, murine LIF was unable to maintain alkaline phosphatase expression of 
fiPSCs (Figure 4a and b). 
 
Feline iPSCs express key pluripotent markers and reactivate Nanog expression 
Feline iPSCs were examined for markers of pluripotent stem cells. Colonies were positive 
for alkaline phosphatase (Figure 5a). In 3 individual clonal fiPSC lines there was high 
expression of feline Nanog, which was not detectable in the original fibroblasts (Figure 
5b). Additionally cells were positive for the surface marker SSEA1 (Figure 5c-e), negative 
for SSEA4 (Figure 5f-h) and positive for nuclear transcription factors Oct4 (Figure 5i-k), 
Sox2 (Figure 5l-n) and Nanog (Figure 5o-q). fiPSC could be passaged >20 times without 
losing proliferative potential, maintained the above phenotype and had a normal 
karyotype (Figure 6). 
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Feline iPSCs are capable of in vitro differentiation into derivatives of the three germ 
layers 
We next sought to assess whether the fiPSC had the potential to differentiate into cells 
representative of the 3 germ layers. fiPSCs seeded onto a low attachment surface in the 
absence of fLIF formed embryoid bodies (EBs, Figure 7a). Outgrowth cells from EBs 
attached to gelatin-coated plates displayed multiple morphologies (Figure 7b). 
Immunostaining revealed that subsets of these cells expressed the mesodermal markers 
smooth muscle actin (Figure 7d) and α-sarcomeric actin (Figure 7f), ectodermal marker 
βIII-tubulin (Figure 7h) and endodermal marker SOX17 (Figure 7j). None of these markers 
were expressed in the undifferentiated iPSCs (Figure 7 c, e, g and i). Together these 
results indicated the in vitro pluripotency of fiPSCs.  
 
Feline iPSCs continue to express viral transgenes 
Feline iPSCs showed expression of the viral transgenes in the infected fibroblasts and in 
three iPSC lines at passage 7 and passage 22 (Figure 8).  Expression levels for Oct4 and 
Sox2 were higher in the iPSC lines compared to the infected fibroblasts (p < 0.05). 
Expression of cMyc was higher in passage 7 iPSCs compared to infected fibroblasts (p < 
0.05). Nanog expression was lower in iPSCs compared with the infected pool, however 
this difference was not significant (p = 0.252 for passage 7 and p = 0.720 for passage 
22). There was no difference in expression levels between passage 7 and passage 22 
iPSCs for any of the transgenes (p = 0.993 for Oct4, p = 0.997 for Sox2, p = 0.223 for 
Klf4, p = 1.00 for cMyc and p = 0.881 for Nanog).  
 16 
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Discussion 
In this study we describe the first generation of induced pluripotent stem cells from the 
domestic cat. We present a number of optimisation steps required for successful iPSC 
generation and anticipate these results will advance feline medical research similar to the 
advances made in human medical research, particularly for genetic diseases [32,33]. 
These new technologies have been widely applied in human neurological and cardiac 
diseases, where patient-specific iPSC lines act as powerful tools as in vitro disease 
models [34–36]. These include new gene therapy strategies for iPSC-dervied cellular 
models of hypertrophic cardiomyopathy [37]. Our work provides the initial steps to 
realising these advancements for feline patients and enhances the potential of cats as 
large animal models for analogous human disease where prospective therapies can be 
rapidly translated from the feline to the human clinic. 
 
A major barrier to inducing pluripotency is the efficient delivery and expression of 
pluripotent genes (Oct4, Sox2, Klf4, cMyc and Nanog; OSKMN) [38]. There are few 
reports on viral delivery of genes in domestic cat cells [39,40]. Initially we trialled feline 
iPSC generation using a Sendai virus based delivery of OSKM (Cytotune 2.0, Thermo 
Fisher), however although the virus was able to infect feline cells, iPSC colonies never 
appeared despite several attempts with various modifications (data not shown).  We then 
selected an MMLV-based retrovirus delivery system as this has been previously reported 
for the generation of iPSCs from wild feline species [19,20]. Additionally this allowed us 
to add Nanog into the reprogramming factors, as this is required for iPSC generation in 
wild felids [20]. This system yielded low transfection efficiencies when replicating 
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conditions used for mouse or human cells. We hypothesised that this was due to slow 
growth of feline fibroblasts in DMEM/10% FBS media since MMLV retrovirus is only able 
to integrate into cells that are undergoing mitosis [41]. In order to increase the proliferation 
of the fibroblasts, media was supplemented with bFGF [42] together with seeding cells 
24 h prior to transfection and at low density to increase the MOI. This led to a maximum 
GFP expression of about 99%. This is in line with retroviral based delivery methods for 
iPSC generation in other species [8,11,20]. We further demonstrated that feline cells are 
able to express the transduced human genes at the mRNA and protein level.   
 
It was also necessary to optimise the conditions for iPSC colony emergence. We 
observed mesenchymal-to-epithelial transition (MET) of fibroblasts within 2-3 days of viral 
transfection, which is thought to be one of the earliest stages in the reprogramming 
process [43]. Under conditions used for human iPSC generation (including KSR and 
bFGF), these epithelial-shaped cells reverted back to a mesenchymal morphology. We 
also observed that if MEFs were added after day 5, no colonies emerged. Since MET was 
occurring within a few days, it appeared that reprogramming in feline cells was following 
a similar timeline as for mouse iPSCs [44], which form quicker than human iPSCs [45]. 
We therefore added iMEFs to the transfected cells and included feline LIF as early as one 
day after virus was removed which yielded colonies with typical ESC and iPSC 
morphology [46]. 
 
These fiPSCs expressed Oct4, Sox2, Nanog and SSEA1 but not SSEA4 similar to mouse 
ES and iPS cells [47]. Further characterisation of the fiPSCs showed they were able to 
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differentiate into cells representing the three germ layers and had a normal karyotype 
after >20 passages. Nanog, a marker of cellular reprogramming [48], was also activated. 
 
Culture conditions for iPSCs from different species show considerable variation between 
publications, which makes determining the optimal conditions for a novel species 
challenging [15]. This difference may be due to the developmental stages represented by 
iPSCs [49]. For example, mouse iPSCs represent a ‘naive’ type pluripotent stem cell, and 
have a domed and phase-bright appearance [50]. However human iPSCs represent a 
‘primed’ pluripotent cell, similar to mouse epiblast cells, with flattened colony morphology 
[51]. Both types can be converted into the other type by adjusting culture conditions 
[52,53]. The naive type relies on LIF for maintenance of pluripotency and self-renewal, 
whereas the primed type is dependent on bFGF [54]. It is less clear where iPSCs derived 
from other species fit along this spectrum, with iPSCs derived from monkeys, pigs, 
horses, cows, goats and dogs fitting both definitions [11,13,14,16,18,55–57]. With respect 
to our feline iPSCs, they closely resemble the naive type, which is substantiated by their 
morphology and surface expression of SSEA1 and not SSEA4, as is the case for mouse 
iPSCs. Specifically feline cells relied on feline LIF, with murine LIF unable to sustain 
alkaline phosphatase expression, and this is likely due to the differences between feline 
and murine LIF protein and receptors [58].  
 
Although we describe conditions for feline iPSCs, there is potential for the system to be 
further optimised.  For example, the use of FBS and iMEFs led to inconsistent colony 
morphology and behaviour. Further optimisation may identify other growth factors or 
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molecules that would enable a more stable phenotype and facilitate feeder cell removal. 
The suboptimal culture conditions in our study may have led to the persistent transgene 
expression that we observed in the feline iPSCs [59]. In human and mouse studies 
transgene expression is expected to cease at around passage 10-15, which was not the 
case for the iPSCs in this study [60]. This is common issue with iPSCs derived from 
domestic animals and where expression of inserted factors has been directly measured 
the majority of reports demonstrate persistent transgene expression [15], as is also the 
case for wild felid iPSCs [19,20]. Although these cells would be useful for in vitro drug 
discovery, continued transgene expression creates an issue for clinical application since 
implantation of these cells may cause tumorigenesis [6], therefore transgene-free feline 
iPSCs would be a useful next step, and this has been the process for human iPSCs.  
 
In conclusion, we sought to establish a platform to generate the first iPSCs from domestic 
cats with the expectation that these will advance feline medicine.  Outcomes from their 
application to the understanding and management of disease is not limited to the cat since 
similarities of genetic pathologies between cats and humans will provide invaluable 
information for human conditions where similar clinical translation is more difficult and 
outcomes take longer. 
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